Engineered zinc-finger protein (ZFP) transcription factors induce the expression of endogenous genes and can be remotely delivered using adenoviral vectors. One such factor, Ad-32Ep65-Flag (Ad-p65), targets and induces expression of vascular endothelial growth factor (VEGF; also called VEGF-A) splice variants in their normal biological stoichiometry. We show that Ad-p65 transfection of primary motor neurons results in VEGF variant expression and a significant increase in axon outgrowth in these cells. Given the neuroprotective effects of VEGF and its ability to increase neurite outgrowth, we examined the efficacy of Ad-p65 to enhance motor neuron regeneration in vivo using rats that have undergone recurrent laryngeal nerve (RLN)-crush injury. Injection of Ad-p65 after RLN crush accelerated the return of vocal fold mobility and the percentage of nerve-endplate contacts in the thyroarytenoid muscle. Overall, adenoviral delivery of an engineered ZFP transcription factor inducing VEGF-A splice variant expression enhances nerve regeneration. ZFP transcription factor gene therapy to increase expression of the full complement of VEGF-A splice variants is a promising avenue for the treatment of nerve injury and neurodegeneration.
Introduction
Injury to the recurrent laryngeal nerve (RLN) results in vocal fold paresis or paralysis. Available treatments for vocal fold paralysis, however, do not restore vocal fold motion but rather provide geometric solutions, either relocating the paralyzed vocal fold closer to midline to improve contact, bypassing obstructions or using reinnervation to restore or preserve laryngeal muscle tone. 1, 2 The future ability to restore vocal fold movement for this dynamic neurological problem depends on strategies for maintaining the survival of axotomized neurons and stimulating axonal regeneration to the appropriate laryngeal muscles. Treatment with neurotrophic growth factors such as vascular endothelial growth factor (VEGF; also called VEGF-A) is one approach that has the potential to preserve and restore functional innervation to axotomized vocal folds. Although VEGF was first characterized as an angiogenic factor, it is known to have neurotrophic effects in the nervous system as well. VEGF is capable of increasing axonal outgrowth, 3, 4 blocking neuronal apoptosis [5] [6] [7] and promoting neurogenesis. 8, 9 Furthermore, VEGF treatment is efficacious in numerous in vitro and in vivo models of neurodegeneration, such as amyotrophic lateral sclerosis and X-linked spinobulbar muscular atrophy. [10] [11] [12] [13] In the nervous system, alternative splicing results in the generation of at least five different VEGF isoforms. 14, 15 Previous studies on the efficacy of VEGF against in vitro and in vivo neurodegeneration have focused on the efficacy of a single VEGF variant, VEGF 165 . [10] [11] [12] [13] During angiogenesis, individual VEGF splice variants show differing roles, and expression of multiple isoforms results in a more robust angiogenic response. [16] [17] [18] [19] [20] [21] Therefore, utilization of the full biological array of VEGF splice variants may offer increased neuroprotection against nerve injury and neurodegeneration. 14, 16, 21 Engineered zinc-finger protein (ZFP) transcription factors induce the expression of endogenous genes. Case and colleagues at Sangamo BioSciences Inc. (Richmond, CA, USA) engineered a ZFP specific for VEGF 20, 22 named 32Ep65-Flag, which induces the expression of VEGF and leads to the production of all naturally occurring splice variants in their normal stoichiometry. 23 In vitro and in vivo expression induces VEGF variant upregulation and stimulates angiogenesis, improves blood flow and accelerates wound healing in animal models of disease. 20, [22] [23] [24] [25] [26] Owing to the challenges of administering growth factors to neurons, 2,27-29 the delivery of viral vectors carrying transgenes encoding or inducing growth factors to injured neurons is a viable alternative. Viral vectors may be delivered to the central nervous system (CNS) by remote injection into peripheral nerves offering easier surgical accessibility, cell selectivity and less risk of CNS injury than from direct injection. 2, 27, 28 Our group and others have established that these adenoviral vectors are carried to the CNS by retrograde transport and result in expression of virally encoded genes. 27, 28, 30, 31 The delivery of neurotrophic growth factors such as insulin-like growth factor-I and glial-derived neurotrophic factor have been examined for their ability to enhance regeneration in in vivo models of RLN injury. 30, [32] [33] [34] The efficacy of VEGF neuroprotection against RLN injury, however, has not yet been examined.
Given the neuroprotective effects of VEGF treatment in vivo for neurodegeneration and the efficacy of inducing the full biological array of VEGF variants in ischemic animal models, we sought to determine whether induction of VEGF expression provides neuroprotection in rodents that have undergone a nerve-crush injury in the RLN. This was accomplished using an adenoviral construct to deliver the ZFP transcription factor to upregulate expression of VEGF splice variants, named Ad-32Ep65-Flag (Ad-p65). We show expression of p65-Flag after transfection of primary motor neurons (MNs) and subsequent upregulation of VEGF in these cells. Injection of Ad-p65 into rats that have undergone nerve-crush injury causes an earlier return of vocal fold mobility, suggesting enhanced nerve regeneration. This approach shows the efficacy of ZFPs to upregulate expression of endogenous neuroprotective genes and holds promise for the treatment of vocal fold paralysis and other forms of nerve injury and neurodegeneration.
Results
Transfection of primary motor neurons and effects of vascular endothelial growth factor upregulation Primary MNs were transfected with Ad-p65 (250 Vg (viral genomes) per MN) after 1 day in culture and fixed 48 h after transfection for immunocytochemistry (ICC). MNs labeled with TUJ1 show successful transfection evidenced by detection of the Flag epitope (Figures 1a  and b) . Successful transfection was further confirmed by detection of the Flag epitope using western blot analysis of cell lysates from transfected MNs (Figure 1c) . Upregulation of VEGF variants after Ad-p65 transfection was confirmed by western blot analysis (Figure 1d ). Dot blot analysis of conditioned media and enzyme-linked immunosorbent assay analysis of cell lysates from transfected MNs also verifies upregulation and secretion of VEGF from MNs, with approximately an 86-fold increase in VEGF levels after transfection with 250 Vg per MN (Figure 1e ; data not shown). To confirm that the upregulation of VEGF by Ad-p65 transfection is capable of inducing functional effects in MNs, we next examined the effect of VEGF upregulation by Ad-p65 on axon outgrowth in MNs. To ensure that any increase in axon length was not influenced by cell-cell mediated mechanisms, MNs were plated at lower plating density to ensure growth of isolated MNs. Transfection with Ad-p65 resulted in a significant increase in axon length, in which upregulation of VEGF resulted in an average length increase of 21% compared with untransfected controls (Figure 2) . Overall, these data show successful upregulation of bioactive VEGF after Ad-p65 transfection of MNs. To determine the neuroprotective effects of Ad-p65 on MNs in vivo, we next examined the effects of Ad-p65 injection on rats that have undergone a right RLN-crush injury. Crush injury to the right RLN results in a unilateral loss of vocal fold movement and loss of motor endplates in the thyroarytenoid muscle. 39 Crush injury to the RLN follows a reproducible timeline for recovery and does not result in loss of MNs in the nucleus ambiguus. 39 Direct laryngoscopy was performed on each animal before termination at 3, 7 or 14 days to examine proper movement of vocal folds. Normal vocal fold movement was present before the initial surgical procedure, and all animals had right vocal fold paralysis in the immediate postoperative period on the basis of observational scoring at direct laryngoscopy. Observational scoring at 3, 7 and 14 days shows an accelerated return of vocal fold movement (Table 1 ). In both experimental and control groups, no return of vocal fold motion occurred at 3 days. At 7 days, significant increases in vocal fold motion occurred in rats that received Ad-p65 injection versus control Ad-GFP. Figure 3 shows the accelerated return of vocal fold movement in Ad-p65-injected rats at 7 days upon direct laryngoscopy. At 14 days, function returned to normal in both groups. These data suggest that Adp65 restores vocal fold motion earlier than untreated rats that received injections of the control vector.
Ad-32Ep65-Flag injection expedites restoration of nerve-endplate contact
Rats killed at 3, 7 and 14 days after crush injury and injection were then analyzed for the percentage of nerveendplate contact (PNEC) for each group (Figure 4 ). Similar to the direct laryngoscopy results, no difference in PNEC was detected between those animals injected with Ad-p65 (28.6 ± 2.2%, N ¼ 5) versus the control adenoviral vector (26.1±1.2%, N ¼ 5) at 3 days. At 7 days post-crush, however, rats receiving the Ad-p65 construct had significantly increased PNEC (71.7±1.6%, N ¼ 5) compared with control rats (29.4 ± 1.6%; N ¼ 4). At 14 days after the procedure, no significant difference in nerve-endplate contact was observed between experimental (69.3±2.1%, N ¼ 4) or control (64.2±4.3%, N ¼ 4) groups, although a trend toward increased recovery was present in the Ad-p65 treated rats. These data show an enhanced restoration of nerve-endplate contact in rats undergoing RLN nerve-crush injury after Ad-p65 injection.
Discussion
Engineered ZFP transcription factors have tremendous potential for the treatment of disease and injury because of their ability to regulate a variety of cellular activities when combined with different functional domains. ZFPs containing the p65 domain of the transcription factor NF-kb can be used to activate transcription of targeted endogenous genes. Using this approach, Case and colleagues at Sangamo BioSciences designed a ZFP specific for VEGF, named 32Ep65. 22 These studies Graphic representation of vocal fold motion data collected at postoperative direct laryngoscopy for control (Ad-GFP) and experimental (Ad-p65) rats. At 7 days, there was significant improvement in vocal fold motion in rats receiving Ad-p65 injection over those in the control group, *Po0.05. analyze the ability of this construct to upregulate expression of bioactive VEGF and provide neuroprotection in an in vivo model of nerve injury. We show expression of the engineered transcription factor, upregulation of VEGF variants, and subsequent effects on axon outgrowth in transfected primary MNs. Furthermore, we show a significant acceleration of vocal fold movement restoration and return of nerve-endplate contact with 32Ep65 treatment in rats that have undergone an experimental RLN-crush injury. Vascular endothelial growth factor is an angiogenic protein that also has neurotrophic properties. VEGF can increase axonal outgrowth, block neuronal apoptosis and promote neurogenesis. [3] [4] [5] [6] [7] [8] [9] In the nervous system, at least five different isoforms of VEGF are generated from alternative splicing of a single gene, which includes VEGF 121 , VEGF 145 , VEGF 165 , VEGF 189 and VEGF 206 . 14, 15 VEGF 165 is the most commonly studied variant and has neuroprotective properties in various models of peripheral nerve disorders such as traumatic injury, diabetic neuropathy, sciatic nerve injury, spinal cord transection and ischemic neuropathy. 26, [40] [41] [42] [43] [44] Efficacy of VEGF 165 for neurodegenerative disease has also been shown in in vitro and in vivo models of amyotrophic lateral sclerosis and a mouse model of spinobulbar muscular atrophy. [10] [11] [12] [13] The full biological array of VEGF isoforms, however, may offer increased efficacy. 14, 16, 21 Roles of the various VEGF splice variants have been previously examined for differential effects on angiogenesis. Expression of the three major VEGF isoforms, VEGF 121 , VEGF 165 and VEGF 189 , confer a more potent angiogenic response in vivo in a murine ischemic hindlimb model compared with expression of VEGF 165 alone. 21 Furthermore, similar studies comparing treatment with differing ratios and combinations of the various isoforms also imply that certain mixtures can provide improved efficacy and safety. 16 Vasculature resulting from such combined treatments not only show accelerated angiogenesis, but also generate less hyperpermeable and more mature vasculature. 16, 20 These results stem from the differential solubility, heparin affinity and ability of the multiple isoforms to activate the various receptors for VEGF including VEGFR2. 45 Taken together, these results imply that expression of the complete array of VEGF variants has the potential for improved neuroprotection.
Expression of the 32Ep65 ZFP promotes the production of all naturally occurring splice variants of VEGF in their normal stoichiometry. 23 In vivo, 32Ep65 induces the expression of VEGF, stimulates angiogenesis and accelerates wound healing. 20 Several additional studies support the use of ZFP induction of VEGF to promote angiogenesis as well as treat experimentally induced peripheral diabetic neuropathy. [24] [25] [26] These data confirm the idea that engineered ZFP transcription factors are able to regulate gene expression in vivo and produce a therapeutic effect 20, 23, 46 and support the use of 32Ep65 to treat RLN nerve-crush injury in the current studies.
We are using the adenoviral construct Ad-p65 to deliver 32Ep65 tagged with a Flag epitope to the nervous system. Adenoviral delivery for gene therapy circumvents many of the limitations of direct pharmacologic therapy with neurotrophic factors for neurological diseases and nerve injury. Most neurotrophic factors such as VEGF are large, do not cross the blood-brain barrier and have poor diffusion capabilities when injected directly into the CNS.
2,27-29 Adenoviral delivery also offers the option for remote injection into peripheral nerves or muscle because viral vectors are carried to the CNS by retrograde transport, thus providing easier surgical accessibility, cell selectivity and less risk for CNS injury. 27, 28 We show successful expression of 32Ep65 after transfection of MNs with Ad-p65 (250 Vg per MN), as evidenced by detection of the Flag epitope in MNs by ICC (Figures 1a and c) . This subsequently induces the upregulation of VEGF variants (Figure 1d ), which are released by MNs (Figure 1e) , and enhance axon outgrowth in transfected MNs (Figure 2 ). These data are consistent with the literature and further validate 32Ep65 efficacy for the induction of VEGF and the enhancement of axonal outgrowth. 3, 4, 20 Gene therapy with neurotrophic factors such as insulin-like growth factor-I and glial-derived neurotrophic factor has been examined previously and enhances recovery after experimental injury to the RLN. 30, [32] [33] [34] These studies are the first to show the efficacy of VEGF variant upregulation for RLN injury. The RLN-crush injury model is a viable model to examine therapeutic interventions and nerve injury. 27 Crush injury to the RLN preserves the neural structure necessary to transport therapeutic substances throughout the axon allowing for remote injection and retrograde transport. Furthermore, it is easily reproducible using standard surgical procedures, ultimately providing a Representative image of nerve-endplate contact after crush injury at 7 days in rats receiving control injection of the Ad-GFP vector (b) or Ad-p65 injection (c). Laryngeal sections were processed for acetylcholine staining (motor endplates, arrows) followed by neurofilament (NF) immunoperoxidase (nerve fibers, arrowheads). A full colour version of this figure is available at the Gene Therapy journal online.
Neuroprotection by VEGF-A gene therapy SA Sakowski et al predictable sequence of denervation followed by reinnervation that is associated with axonal sprouting within the preserved neural structure. 30 Results from our laboratory show a reproducible time course for reinnervation and recovery after nerve-crush injury in rats that established reinnervation initiating between weeks 1 and 2 after injury, which reaches completion by week 3. 39 Reinnervation is measured by calculating the PNEC and subsequent functional recovery is measured by direct laryngoscopy. The level of reinnervation achieved by week 3 is comparable with levels in control (noncrushed) nerves as reported previously at 86.8% PNEC. 39 Our data support this timeline for control rats, in which we see a return of vocal fold motion and an increase in PNEC at the 14 day time point (Table 1; Figure 4 ) that resembles the PNEC levels reported previously. 39 Experimental rats, on the other hand, showed a significant recovery by 7 days in both PNEC and vocal fold mobility, indicative of a substantial enhancement in the recovery rate for rats treated with Ad-p65 (Table 1 ; Figures 3 and 4) .
Injection of adenoviral constructs into the RLN after crush injury promotes expression of virally encoded genes in MNs of the nucleus ambiguus. 27, 28, 30 On the basis of our in vitro results showing secretion of VEGF from MNs (Figures 1e and f) , it is possible that in addition to direct neuroprotective effects of VEGF on MNs, the beneficial effects of Ad-p65 treatment could be mediated indirectly through effects of VEGF on cells near the injection site or neighboring cells in the MN microenvironment. VEGF stimulates the survival and invasion of Schwann cells, which can have a role in axonal regeneration. [47] [48] [49] Schwann cells, MN axons and endoneurial cells all express VEGF receptors, further supporting the possibility that multiple cell types may be affected by Ad-p65 VEGF upregulation and contribute to neuroprotection. 41, [47] [48] [49] Additional studies are warranted to determine the precise mechanisms and contributions of cell types affected by VEGF in protection against nerve injury and neurodegeneration after Ad-p65 gene therapy.
Although nerve crush is an excellent model for experimentation, 39, 50, 51 additional studies in other models of nerve injury and neurodegeneration are warranted to establish upregulation of VEGF variants using ZFP gene therapy as an efficacious model for the treatment of neurodegeneration associated with both injury and disease. In addition, adenoviral delivery of 32Ep65 can be restricted by the limited duration of expression of the constructs. For example, the loss of significance between the 7-and 14-day control and experimental groups could be the result of decreased expression of the ZFP transcription factor. Future studies using an adenoviralassociated virus, which is capable of overcoming the host immune response and is reported to have limited toxic effects and prolonged gene expression in vivo, 52 could potentially overcome these limitations.
Overall, these studies validate the use of gene therapy with the 32Ep65 ZFP to induce the full biological array of VEGF splice variants and enhance neuronal recovery after RLN-crush injury. We show successful transfection of MNs in vitro after viral transfection with Ad-p65, and a subsequent upregulation in VEGF that confers beneficial effects on axon outgrowth. In vivo, Ad-p65 treatment of rats after RLN-crush injury accelerates the return of vocal fold mobility and increases PNEC at 7 days after the crush injury. These data support the further investigation of gene therapy using the 32Ep65 ZFP to upregulate the complete biological array of VEGF variants for the treatment of nerve injury and neurodegeneration.
Materials and methods

Primary motor neuron culture
Primary MNs were isolated from E15 Sprague-Dawley rat embryos according to our previously published protocol. 35 For culturing of primary MNs, MN density was adjusted to between 2 Â 10 4 and 2 Â 10 6 MN ml -1 and 50 ml of the suspension was applied to poly-Llysine-coated glass coverslips in a 24-well plate, or 500 ml of the suspension was applied to poly-Llysine-coated 12-well plates. After 24 h, the MNs were fed with growth media.
Viral transfection of primary motor neurons and analysis
Ad-32Ep65-Flag was a gift from Sangamo BioSciences Inc. Viral transfection of primary MNs was performed as described previously. 36 Briefly, virus (0-250 Vg per MN) was added after 24 h in culture and MNs were incubated for 48 h before fixing for ICC and collection of cell lysates to show successful transfection of MNs, or harvesting conditioned media to show VEGF expression.
For ICC, cells were plated at 50 cell mm -2 on poly-Dlysine-coated glass coverslips followed by fixation in 4% PFA for 5 min. Immunostaining was carried out by standard protocols as described previously. 37 Primary antibodies used include Flag (Sigma-Aldrich Co., St Louis, MO, USA) and TUJ1 (Neuromics, Edina, MN, USA). Cells were then incubated in appropriate Alexafluor-conjugated secondary antibody (Molecular Probes, Invitrogen, Carlsbad, CA, USA) followed by mounting in ProLong Gold (Molecular Probes, Invitrogen). Images were collected using an Olympus BX-51 microscope. Neurite length was quantified using ImageJ software (ImageJ, US National Institutes of Health, Bethesda, MD, USA, http://rsb.info.nih.gov/ij/). Ten images per condition were taken at random in three separate experiments for a total of at least 30 MNs per condition. Axon length was traced from the periphery of the cell body to the tip of the axon.
Conditioned media from MNs and cell lysates were collected 48 h after transfection and western blotting, dot blot analysis or enzyme-linked immunosorbent assay was performed as described previously. 36 Briefly, for western blotting, cell lysates were prepared by scraping cells in RIPA buffer (20 mM Tris, pH 7.4), 150 mM NaCl, 1 mM EDTA, 0.1% SDS, 1 mM Na deoxycholate, 1% Triton X-100, 0.1% trypsin units per ml aprotinin, 10 mg ml -1 leupeptin and 50 mg ml -1 PMSF. Equal amounts of protein were loaded in each lane of a 12.5% polyacrylamide gel and separated by electrophoresis before transferring onto nitrocellulose membranes. For dot blot analysis, protein was balanced and loaded onto nitrocellulose membranes. Dot blot and western blot membranes were incubated with primary antibody overnight at 4 1C, and incubated with the appropriate horseradish peroxidase-conjugated secondary antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) for 1 h at room 
Animal surgery
All animals used for these studies were housed in a pathogen-free environment and cared for following the University of Michigan Committee on the Care and Use of Animals guidelines. Animal care standards described in the National Institutes of Health Guide for Care and Use of Laboratory Animals are adhered to in order to ensure limited discomfort and distress. Thirty Sprague-Dawley rats weighing 300-350 g underwent inhalational anesthesia with isoflurane (Baxter Caribe Inc., Deerfield, IL, USA) followed by anterior tongue retraction to expose the epiglottis. After bilateral symmetric vocal fold movement was confirmed by direct laryngoscopy, intubation was performed with a 16-gauge angiocatheter. General anesthesia was maintained using a Harvard Rat Ventilator (Harvard Apparatus, Holliston, MA, USA) and supplemental oxygen was provided. After sterile preparation of the anterior neck skin, a vertical cervical incision was made separating the platysma muscles. The submandibular glands and strap muscles were identified and separated to reveal the larynx, trachea and thyroid gland. Using a dissecting microscope (Stereozoom 6, Leica, Buffalo, NY, USA), the right RLN was exposed and circumferentially dissected from the mid-trachea to the inferior margin of the right thyroid gland. The nerve was then crushed with jeweler's forceps at the level of the sixth tracheal ring for 30 s. After viral injection (described below), the strap muscles and submandibular glands were reapproximated followed by skin closure using staples. Direct laryngoscopy was again performed at the termination of the crush/injection procedure and just before killing to quantify right-sided vocal fold motion impairment. Vocal fold motion was observed during suspension, and movement scored on a graded scale from 0 to 1 (0 indicated no motion of ipsilateral fold, 1 indicated normal motion with complete glottic closure). Direct laryngoscopy was performed in a blinded manner by one of the investigators.
The study began with five rats in each group for the initial procedure as indicated above. In the 7 day group, one experimental rat died on postoperative day 3, presumably from a wound infection. In the 14 day group, one rat in both the experimental and the control group was lost during postoperative direct laryngoscopy.
Viral injection
Rats were randomly assigned to six groups-three control groups and three experimental groups. Different time points to kill were the only differences between groups within the control or experimental arms of the study. In the control animals receiving crush injury, a control adenoviral vector (Ad/CMV-GFP; Ad-GFP) was injected into the RLN at a concentration of 1.2 Â 10 7 pfu. Animals in the three experimental groups underwent RLN injection after crush injury using Ad-p65 at 0.9 Â 10 7 pfu. 31 Specifically, after identification of the nerve, a 3-0 silk suture was passed around the nerve and gentle countertraction applied. A 50 mm tapered micropipette (glass micropipette puller PP-83; Narishige, Tokyo, Japan) was advanced beneath the perineurium along the nerve proximal to the site of crush injury. Using an oocyte microinjector and micromanipulator (Nanoject; Drummond, Broomall, PA, USA), 1.5 ml of virus was injected in 50 nl boluses (5% volume error). This dose results in maximal adenoviral transgene expression. 38 
Tissue processing and analysis
Rats were killed at 3, 7 or 14 days after crush injury and injection. Injection with Fatal-Plus Solution (Vortech Pharmaceuticals, Dearborn, MI, USA) was followed by intracardiac perfusion with buffered 4% paraformaldehyde. Laryngectomy was performed followed by cryoprotection in phosphate buffer with 20% sucrose and embedding in Tissue-Tek OCT Compound (Sakura Finetek USA Inc., Torrance, CA, USA). Laryngectomy tissue samples were cryosectioned in 20 mm axial sections through the long axis of the thyroarytenoid muscle. Cryosections (20 mm) of the thyroarytenoid muscle underwent acetylcholinesterase staining to identify motor endplates followed by neurofilament immunoperoxidase to identify nerve fibers as described previously. 27 Images were obtained using an Olympus BX-51 microscope (Olympus America, Inc., Center Valley, PA, USA).
Statistical analyses
Statistical significance between control and Ad-p65-transfected MN axon length was calculated using analysis of variance followed by Tukey's multiple comparison test and standard t-tests (GraphPad Software Inc., La Jolla, CA, USA). The PNEC in the thyroarytenoid muscle sections was determined as an objective measure of innervation status, by counting the total number of motor endplates making contact with neurofilament divided by the total number of nerve endplates on each section. Counting was performed in a blinded manner under light microscopy by one of the investigators and verified by a second investigator and results averaged. Approximately every seventh section was analyzed. Analysis of variance with the Bonferroni multiple comparisons test and standard t-tests were used to compare the mean percentage of neurofilament/ nerve-endplate contact between rats within the same group. A P-value of o0.05 was considered significant.
